Differences in Colistin-resistant Acinetobacter baumannii Clinical Isolates Between Patients With and Without Prior Colistin Treatment
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The increasing morbidity and mortality rates associated with Acinetobacter baumannii are due to the emergence of drug resistance and the limited treatment options. We compared characteristics of colistin-resistant Acinetobacter baumannii (CR-AB) clinical isolates recovered from patients with and without prior colistin treatment. We assessed whether prior colistin treatment affects the resistance mechanism of CR-AB isolates, mortality rates, and clinical characteristics. Additionally, a proper method for identifying CR-AB was determined. Methods: We collected 36 non-duplicate CR-AB clinical isolates resistant to colistin. Antimicrobial susceptibility testing, Sanger sequencing analysis, molecular typing, lipid A structure analysis, and in vitro synergy testing were performed. Eleven colistin-susceptible AB isolates were used as controls. Results: Despite no differences in clinical characteristics between patients with and without prior colistin treatment, resistance-causing genetic mutations were more frequent in isolates from colistin-treated patients. Distinct mutations were overlooked via the Sanger sequencing method, perhaps because of a masking effect by the colistin-susceptible AB subpopulation of CR-AB isolates lacking genetic mutations. However, modified lipid A analysis revealed colistin resistance peaks, despite the population heterogeneity, and peak levels were significantly different between the groups. Conclusions: Although prior colistin use did not induce clinical or susceptibility differences, we demonstrated that identification of CR-AB by sequencing is insufficient. We propose that population heterogeneity has a masking effect, especially in colistin non-treated patients; therefore, accurate testing methods reflecting physiological alterations of the bacteria, such as phosphoethanolamine-modified lipid A identification by matrix-assisted laser desorption ionization-time of flight, should be employed.
Abstract
Background: The increasing morbidity and mortality rates associated with Acinetobacter baumannii are due to the emergence of drug resistance and the limited treatment options. We compared characteristics of colistin-resistant Acinetobacter baumannii (CR-AB) clinical isolates recovered from patients with and without prior colistin treatment. We assessed whether prior colistin treatment affects the resistance mechanism of CR-AB isolates, mortality rates, and clinical characteristics. Additionally, a proper method for identifying CR-AB was determined. Methods: We collected 36 non-duplicate CR-AB clinical isolates resistant to colistin. Antimicrobial susceptibility testing, Sanger sequencing analysis, molecular typing, lipid A structure analysis, and in vitro synergy testing were performed. Eleven colistin-susceptible AB isolates were used as controls. Results: Despite no differences in clinical characteristics between patients with and without prior colistin treatment, resistance-causing genetic mutations were more frequent in isolates from colistin-treated patients. Distinct mutations were overlooked via the Sanger sequencing method, perhaps because of a masking effect by the colistin-susceptible AB subpopulation of CR-AB isolates lacking genetic mutations. However, modified lipid A analysis revealed colistin resistance peaks, despite the population heterogeneity, and peak levels were significantly different between the groups. Conclusions: Although prior colistin use did not induce clinical or susceptibility differences, we demonstrated that identification of CR-AB by sequencing is insufficient. We propose that population heterogeneity has a masking effect, especially in colistin non-treated patients; therefore, accurate testing methods reflecting physiological alterations of the bacteria, such as phosphoethanolamine-modified lipid A identification by matrix-assisted laser desorption ionization-time of flight, should be employed.
참고문헌 (40)
- Agodi A, "Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals", J Hosp Infect, 86, pp.260~266 (2014)
- Cai Y, "Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies", J Antimicrob Chemother, 67, pp.1607~1615 (2012)
- Li J, "Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii", Antimicrob Agents Chemother, 50, pp.2946~2950 (2006)
- Peleg AY, "Hospital-acquired infections due to Gram-negative bacteria", N Engl J Med, 362, pp.1804~1813 (2010)
- Amudhan SM, "OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii", Indian J Med Microbiol, 29, pp.269~274 (2011)
- Evans BA, "OXA beta-lactamases", Clin Microbiol Rev, 27, pp.241~263 (2014)
- Karaiskos I, "Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review", Int J Antimicrob Agents, 41, pp.499~508 (2013)
- Nation RL, "Colistin in the 21st century", Curr Opin Infect Dis, 22, pp.535~543 (2009)
- Newton BA, "The properties and mode of action of the polymyxins", Bacteriol Rev, 20, pp.14~27 (1956)
- Schindler M, "Interaction of divalent cations and polymyxin B with lipopolysaccharide", Biochemistry, 18, pp.4425~4430 (1979)
- Falagas ME, "Resistance to polymyxins: Mechanisms, frequency and treatment options", Drug Resist Updat, 13, pp.132~138 (2010)
- Koch-Weser J, "Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy", Ann Intern Med, 72, pp.857~868 (1970)
- Meletis G, "Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae", J Antimicrob Chemother, 66, pp.946~947 (2011)
- Pournaras S, "Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems", J Med Microbiol, 56, pp.66~70 (2007)
- Yau W, "Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme", J Infect, 58, pp.138~144 (2009)
- Hood MI, "Genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii", Infect Immun, 81, pp.542~551 (2013)
- Moffatt JH, "Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production", Antimicrob Agents Chemother, 54, pp.4971~4977 (2010)
- Adams MD, "Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system", Antimicrob Agents Chemother, 53, pp.3628~3634 (2009)
- Lee H, "The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica", J Bacteriol, 186, pp.4124~4133 (2004)
- Liu YY, "Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study", Lancet Infect Dis, 16, pp.161~168 (2016)
- Kim Y, "In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment", Diagn Microbiol Infect Dis, 79, pp.362~366 (2014)
- Beceiro A, "Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii", Antimicrob Agents Chemother, 58, pp.518~526 (2014)
- Hraiech S, "Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia", Antimicrob Agents Chemother, 57, pp.5120~5121 (2013)
- López-Rojas R, "Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness", Antimicrob Agents Chemother, 57, pp.4587~4589 (2013)
- Jones CL, "In vivo fitness adaptations of colistin-resistant Acinetobacter baumannii isolates to oxidative stress", Antimicrob Agents Chemother, 61 (2017)
- López-Rojas R, "Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii", J Infect Dis, 203, pp.545~548 (2011)
- CLSI, "Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI supplement M100–S26", Clinical and Laboratory Standards Institute, ~ (2016)
- "Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI–EUCAST Polymyxin Breakpoints Working Group" (2016)[URL]
- Orhan G, "Synergy Tests by E Test and checkerboard methods of antimicrobial combinations against Brucella melitensis", Journal of Clinical Microbiology, 43, pp.140~143 (2005)
- Woodford N, "Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp", Int J Antimicrob Agents, 27, pp.351~353 (2006)
- Cicek AC, "OXA- and GES-type beta-lactamases predominate in extensively drug-resistant Acinetobacter baumannii isolates from a Turkish University Hospital", Clin Microbiol Infect, 20, pp.410~415 (2014)
- Segal H, "Is IS(ABA-1) customized for Acinetobacter?", FEMS Microbiol Lett, 243, pp.425~429 (2005)
- Beceiro A, "Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system", Antimicrob Agents Chemother, 55, pp.3370~3379 (2011)
- Tenover FC, "Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing", J Clin Microbiol, 33, pp.2233~2239 (1995)
- Pittet D, "Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality", Jama, 271, pp.1598~1601 (1994)
- Hawley JS, "Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy", Antimicrob Agents Chemother, 52, pp.351~352 (2008)
- Moosavian M, "Post neurosurgical meningitis due to colistin heteroresistant Acinetobacter baumannii", Jundishapur J Microbiol, 7, pp.e12287~ (2014)
- Eilertson B, "High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates", Antimicrob Agents Chemother, 58, pp.3270~3275 (2014)
- Pholwat S, "Digital PCR to detect and quantify heteroresistance in drug resistant Mycobacterium tuberculosis", PLoS One, 8, pp.e57238~ (2013)
- Rohlin A, "Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques", Hum Mutat, 30, pp.1012~1020 (2009)